Premium
P4‐009: TRIAL OF OXALOACETATE IN ALZHEIMER'S DISEASE (TOAD): INTERIM FDG PET ANALYSIS
Author(s) -
Vidoni Eric D.,
Clutton Jonathan,
Becker Annette M.,
Sherry Erica,
Bothwell Rebecca,
Mahnken Jonathan D.,
Wilkins Heather M.,
Lee Phil,
Choi In-Young,
Brooks William,
Reed Greg,
Burns Jeffrey M.,
Swerdlow Russell H.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2411
Subject(s) - positron emission tomography , medicine , fluorodeoxyglucose , nuclear medicine , pharmacodynamics , endocrinology , pharmacokinetics
Mild-to-Moderate AD Doneoezil Placebo 0.64 (0.24 to 1.04) 1.91 (1.08 to 2.76) 3.02 (1.30 to 4.76) 1.81 (0.37 to 3.03) Galantamine Placebo 0.62 (0.01 to 1.21) 2.83 (1.87 to 3.77) 2.18 (1.04 to 3.14) 1.26 (-0.27 to 2.69) Memantine Placebo 0.21 (-0.48 to 0.91) 1.68 (-0.81 to 4.17) -0.16 (-1.95 to 1.64) 3.08 (0.62 to 5.35) Rivastigmine Placebo 1.08 (0.63 to 1.53) 1.90 (0.74 to 3.07) 2.26 (0.61 to 3.95) 0.98 (-1.30 to 3.17) Memantine + AChEI Placebo 0.25 (-0.5 to 1.01) 2.28 (-0.27 to 4.86) -0.61 (-2.36 to 1.07) 0.30 (-5.39 to 6.00) Galantamine Doneoezil -0.02 (-0.63 to 0.57) 0.91 (-0.24 to 2.04) -0.84 (-2.72 to 0.97) -0.54 (-2.08 to 1.12) Memantine Doneoezil -0.43 (-1.13 to 0.28) -0.24 (-2.77 to 2.28) -3.18 (-5.61 to-0.71) 1.27 (-0.90 to 3.41) Rivastigmine Doneoezil 0.44 (-0.09 to 0.98) -0.01 (-1.30 to 1.28) -0.76 (-3.14 to 1.66) -0.83 (-3.07 to 1.58) Memantine + AChEI Doneoezil -0.39 (-1.18 to 0.41) 0.37 (-2.27 to 3.00) -3.62 (-6.00 to-1.25) -1.51 (-7.20 to 4.28) Memantine Galantamine -0.41 (-1.20 to 0.41) -1.15 (-3.78 to 1.50) -2.34 (-4.18 to-0.38) 1.81 (-0.83 to 4.33) Rivastigmine Galantamine 0.46 (-0.20 to 1.14) -0.93 (-2.31 to 0.48) 0.08 (-1.70 to 2.04) -0.28 (-2.65 to 2.10) Memantine + AChEl Galantamine -0.37 (-1.21 to 0.50) -0.54 (-3.04 to 1.98) -2.78 (-4.51 to-1.03) -0.96 (-6.72 to 4.82) Rivastigmine Memantine 0.87 (0.10 to 1.63) 0.22 (-2.49 to 2.94) 2.42 (0.29 to 4.60) -2.09 (-5.10 to 1.07) Memantine + AChEI Memantine 0.04 (-0.77 to 0.86) 0.61 (-2.95 to 4.17) -0.45 (-1.92 to 0.89) -2.77 (-8.82 to 3.36) Memantine + AChEI Rivastigmine -0.83 (-1.58 to -0.07) 0.38 (-2.19 to 2.97) -2.87 (-4.87 to-0.96) -0.68 (-5.90 to 4.56) Moderate-to-Severe AD Doneoezil Placebo 0.76 (-1.07 to 2.60) 1.01 (-0.87 to 2.74) -0.34 (-4.90 to 3.96) Galantamine Placebo Memantine Placebo 0.08 (-1.74 to 1.78) 3.02 (-9.30 to 15.46) 0.56 (-1.42 to 2.51) 3.00 (-0.50 to 6.68) Rivastigmine Placebo 0.10 (-2.85 to 3.09) -2.93 (-7.93 to 2.01) 3.08 (-1.22 to 7.29) Memantine + AChEI Placebo 1.23 (-1.22 to 3.80) 1.26 (-1.56 to 3.81) 3.05 (-5.67 to 11.55) Galantamine Doneoezil Memantine Doneoezil -0.69 (-3.14 to 1.65) -0.46 (-3.08 to 2.28) 3.34 (-2.14 to 9.27) Rivastigmine Donepezil -0.67 (-3.64 to 2.32) 2.07 (-1.81 to 5.95) Memantine + AChEI Doneoezil 0.46 (-1.54 to 2.60) 0.24 (-1.83 to 2.21) 3.39 (-4.01 to 10.79) Rivastigmine Galantamine Memantine Galantamine Memantine + AChEI Galantamine Rivastigmine Memantine 0.02 (-3.31 to 3.49) -5.95 (-19.33 to 7.28) 2.52 (-2.23 to 7.17) Memantine + AChEI Memantine 1.15 (-1.62 to 4.13) 0.70 (-2.75 to 3.94) 0.05 (-9.51 to 9.20) Memantine + AChEI Rivastigmine 1.13 (-2.34 to 4.72) -1.83 (-6.24. to 2.52)